Dexcom Inc Stock Performance
| DXCM Stock | USD 134.30 0.44 0.33% |
DexCom has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.07, which means a somewhat significant risk relative to the market. DexCom returns are very sensitive to returns on the market. As the market goes up or down, DexCom is expected to follow. DexCom Inc right now shows a risk of 2.28%. Please confirm DexCom Inc skewness, and the relationship between the potential upside and rate of daily change , to decide if DexCom Inc will be following its price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in DexCom Inc are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy fundamental indicators, DexCom is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 0.33 | Five Day Return (2.70) | Year To Date Return 9.11 | Ten Year Return 1.4 K | All Time Return 4.5 K |
Last Split Factor 4:1 | Last Split Date 2022-06-13 |
1 | Should You Hold Shopify for the Long Term | 03/07/2024 |
2 | Medical Devices ETF Hits 52-Week High Stocks to Watch | 03/13/2024 |
3 | Disposition of 1003 shares by Matthew Dolan of DexCom at 131.3912 subject to Rule 16b-3 | 03/15/2024 |
4 | Heres How Much 1000 Invested In DexCom 15 Years Ago Would Be Worth Today | 03/25/2024 |
5 | Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 430 p.m. Eastern Time | 04/02/2024 |
6 | DexCom, Inc. is Attracting Investor Attention Here is What You Should Know | 04/04/2024 |
7 | Stocks Showing Improving Market Leadership DexCom Earns 84 RS Rating | 04/08/2024 |
8 | Dexcom CEO Kevin Sayer sells shares worth over 6.8 million | 04/10/2024 |
9 | Tandem Diabetes shares target raised, Hold rating retained by CFRA | 04/11/2024 |
10 | Disposition of 1990 shares by Matthew Dolan of DexCom at 137.81 subject to Rule 16b-3 | 04/15/2024 |
11 | Dexcom executive sells 274k worth of company stock | 04/16/2024 |
12 | Reasons to Retain DexCom Stock in Your Portfolio for Now | 04/18/2024 |
| Begin Period Cash Flow | 643.3 M |
DexCom |
DexCom Relative Risk vs. Return Landscape
If you would invest 12,929 in DexCom Inc on January 20, 2024 and sell it today you would earn a total of 501.00 from holding DexCom Inc or generate 3.88% return on investment over 90 days. DexCom Inc is currently generating 0.0865% in daily expected returns and assumes 2.2831% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than DexCom, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
DexCom Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for DexCom's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as DexCom Inc, and traders can use it to determine the average amount a DexCom's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0379
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | DXCM | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.28 actual daily | 20 80% of assets are more volatile |
Expected Return
| 0.09 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average DexCom is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of DexCom by adding it to a well-diversified portfolio.
DexCom Fundamentals Growth
DexCom Stock prices reflect investors' perceptions of the future prospects and financial health of DexCom, and DexCom fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DexCom Stock performance.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0641 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 51.64 B | ||||
| Shares Outstanding | 385.52 M | ||||
| Price To Earning | 245.31 X | ||||
| Price To Book | 25.38 X | ||||
| Price To Sales | 14.49 X | ||||
| Revenue | 3.62 B | ||||
| Gross Profit | 1.88 B | ||||
| EBITDA | 916.7 M | ||||
| Net Income | 541.5 M | ||||
| Cash And Equivalents | 2.37 B | ||||
| Cash Per Share | 6.14 X | ||||
| Total Debt | 2.59 B | ||||
| Debt To Equity | 1.17 % | ||||
| Current Ratio | 3.77 X | ||||
| Book Value Per Share | 5.37 X | ||||
| Cash Flow From Operations | 748.5 M | ||||
| Earnings Per Share | 1.30 X | ||||
| Market Capitalization | 51.77 B | ||||
| Total Asset | 6.26 B | ||||
| Retained Earnings | 1.02 B | ||||
| Working Capital | 2.87 B | ||||
| Current Asset | 231.3 M | ||||
| Current Liabilities | 66.9 M | ||||
About DexCom Performance
To evaluate DexCom Inc Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when DexCom generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare DexCom Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand DexCom Inc market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents DexCom's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 153.18 | 160.84 | |
| Return On Tangible Assets | 0.09 | 0.09 | |
| Return On Capital Employed | 0.13 | 0.13 | |
| Return On Assets | 0.09 | 0.09 | |
| Return On Equity | 0.26 | 0.27 |
Things to note about DexCom Inc performance evaluation
Checking the ongoing alerts about DexCom for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DexCom Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DexCom Inc is unlikely to experience financial distress in the next 2 years | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Reasons to Retain DexCom Stock in Your Portfolio for Now |
- Analyzing DexCom's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DexCom's stock is overvalued or undervalued compared to its peers.
- Examining DexCom's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DexCom's management team can have a significant impact on its success or failure. Reviewing the track record and experience of DexCom's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DexCom's stock. These opinions can provide insight into DexCom's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.81 | Earnings Share 1.3 | Revenue Per Share 9.384 | Quarterly Revenue Growth 0.269 | Return On Assets 0.0641 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.